Ionara Bio is developing novel, proprietary small molecules that target and block the TRPV2 channel. TRPV2 is a key player in inflammatory responses, particularly those involving macrophages, that negatively impact cardiac structure and function after an acute myocardial infarction (AMI). The company's lead candidate, a first-in-class TRPV2 inhibitor, is designed to improve cardiac function and reduce pathological cardiac fibrosis, ultimately leading to significantly enhanced cardiac recovery post-AMI.